Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...

Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.

Megan Chacon, a principal at Fish & Richardson and a member of the firm’s life sciences industry team, answers questions ...

Paul Romness had over two decades of experience as a public and policy affairs expert when his daughter’s best friend’s osteosarcoma diagnosis inspired a new career trajectory.

Imagine a gem hunter facing a vast and uncharted landscape to uncover a single beautiful diamond. It is a bit like drug ...

A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.

Life sciences companies face challenges transitioning from R&D to clinical trials due to outdated, fragmented technology systems that struggle to support the complexity of later trial phases.